ADG126

ADG126 is a monoclonal antibody developed by Adagene and Sanofi. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4. ClinicalTrials.gov describes the intervention as: ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hepatocellular carcinoma. The largest, NCT05584670, plans to enrol 542 participants with primary completion expected 2027-01-19. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.